A17

• UNSPSC Description:

  A17 is a bile acid analog with anti-non-alcoholic steatohepatitis (NASH) and anti-inflammatory activities. A17 reduces fatty acid (FA) uptake and promotes FA oxidation though inhibiting fatty acid translocase (Cd36) expression and activating AMPKα. A17 can be used for NASH research[1].

• Target Antigen:

  AMPK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;PI3K/Akt/mTOR

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/a17.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=CO[C@@H]1[C@]2([H])[C@@](CC[C@]3([C@@]2([H])CC[C@]3([H])[C@H](C)CCC(N[C@H](CO)C(C)C)=O)C)([H])[C@@]4([C@](C[C@@H](CC4)OC=O)([H])C1)C

• Molecular Weight:

  533.74

• References & Citations:

  [1]Wang Y, et al. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicol Appl Pharmacol. 2020 Oct 1;404:115169.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2568186-47-8